ALIGOS THERAPEUTICS INC's ticker is ALGS and the CUSIP is 01626L105. A total of 42 filers reported holding ALIGOS THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,725,394 | -23.1% | 2,309,764 | 0.0% | 0.04% | -18.8% |
| Q2 2023 | $2,242,781 | +11.1% | 2,309,764 | 0.0% | 0.05% | +33.3% |
| Q1 2023 | $2,018,734 | -8.3% | 2,309,764 | 0.0% | 0.04% | -21.7% |
| Q4 2022 | $2,200,974 | -15.4% | 2,309,764 | -2.3% | 0.05% | -32.4% |
| Q3 2022 | $2,602,000 | -9.1% | 2,365,064 | 0.0% | 0.07% | +11.5% |
| Q2 2022 | $2,862,000 | -43.7% | 2,365,064 | 0.0% | 0.06% | -42.5% |
| Q1 2022 | $5,085,000 | -81.9% | 2,365,064 | 0.0% | 0.11% | -75.6% |
| Q4 2021 | $28,073,000 | -23.5% | 2,365,064 | 0.0% | 0.43% | -9.6% |
| Q3 2021 | $36,682,000 | -16.9% | 2,365,064 | +9.2% | 0.48% | +5.7% |
| Q2 2021 | $44,135,000 | -10.4% | 2,165,064 | 0.0% | 0.45% | -6.8% |
| Q1 2021 | $49,234,000 | -17.8% | 2,165,064 | 0.0% | 0.49% | +2.3% |
| Q4 2020 | $59,864,000 | – | 2,165,064 | – | 0.48% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 2,320,381 | $2,028,013 | 4.23% |
| TANG CAPITAL MANAGEMENT LLC | 3,424,800 | $2,993,275 | 0.45% |
| Pivotal bioVenture Partners Investment Advisor LLC | 743,215 | $649,570 | 0.27% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 631,887 | $552,269 | 0.23% |
| Vivo Capital, LLC | 3,547,030 | $3,100,104 | 0.22% |
| Newtyn Management, LLC | 1,021,461 | $892,757 | 0.18% |
| Logos Global Management LP | 1,000,000 | $874,000 | 0.12% |
| EcoR1 Capital, LLC | 3,948,360 | $3,450,867 | 0.11% |
| HHLR ADVISORS, LTD. | 2,309,764 | $2,018,734 | 0.04% |
| Baker Brothers Advisors | 2,076,400 | $1,814,774 | 0.01% |